Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with... http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The Lancet Oncology Unpaywall
 
/lp/unpaywall/ibrutinib-for-previously-untreated-and-relapsed-or-refractory-chronic-ndJKDYlqrL

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Unpaywall
ISSN
1470-2045
DOI
10.1016/s1470-2045(14)71182-9
Publisher site
See Article on Publisher Site

Abstract

Journal

The Lancet OncologyUnpaywall

Published: Feb 1, 2015

There are no references for this article.